Join to view full profile
1500 E Duarte RdDepartment of Hematology HCTDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-408-3911
Dr. Aldoss is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2011 - 2012
Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 2007 - 2010
Jordan University of Science and Technology FOMClass of 2006
Certifications & Licensure
CA State Medical License 2010 - 2028
IA State Medical License 2009 - 2012
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Sunrise Acute Care, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2016-2017
Clinical Trials
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Start of enrollment: 2020 Oct 20
- Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Start of enrollment: 2022 Mar 17
Roles: Principal Investigator, Contact
- BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL Start of enrollment: 2021 May 18
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- CAR T‑Cell Therapy as a Bridging Strategy to Second Transplant in Relapsed B‑Cell ALL.Vaibhav Agrawal, Haoyue Shan, Monzr Al Malki, Amandeep Salhotra, Ahmed Aribi
Transplantation and Cellular Therapy. 2026-10-03 - Clinical outcomes of adults with-mutated or rearranged B-cell acute lymphoblastic leukemia.Rick Y Lin, Jose Tinajero, Zhaohui Gu, Vaibhav Agrawal, Hoda Pourhassan
Leukemia & Lymphoma. 2026-10-01 - Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.Tamer Othman, Vaibhav Agrawal, Joo Y Song, Zhaohui Gu, Paul Koller
American Journal of Hematology. 2026-10-01
Journal Articles
- Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic LeukaemiaMichael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
Abstracts/Posters
- Biomarker Modulation By Mivebresib (ABBV-075) +/_ Venetoclax in Relapsed/Refractory Acute Myeloid LeukemiaIbrahim Aldoss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with BlinatumomabIbrahim Aldoss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab OzogamicinIbrahim Aldoss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in AdultsClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
From Novel Therapies to First-in-Human Trials, City of Hope Advances Blood Cancer Care at the American Society of Hematology (ASH) Annual ConferenceDecember 8th, 2025- PeproMene Bio’s PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual MeetingNovember 20th, 2025
- City of Hope to Showcase Advances in Blood Cancer, Microbiome, and Cellular Therapy Research at ASH 2025November 12th, 2025
Grant Support
- BAFF-R CAR T cell therapy for ALLBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: